Bionano Genomics (BNGO)
NASDAQ:BNGO
Want to see BNGO full AI Analyst Report?
Top Page
BioNano Genomics
(NASDAQ:BNGO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.00
▼(-38.27% Downside)
Action:Reiterated
Date:06/06/26
The score is held down primarily by weak financial performance (shrinking TTM revenue, large losses, and ongoing negative free cash flow). Offsetting that, the latest earnings call pointed to improving commercialization indicators and margins with reaffirmed 2026 revenue guidance, while technicals are modestly supportive. Valuation offers limited support due to losses, and corporate events are mixed with both debt retirement and notable leadership changes.
Positive Factors
Consumables Recurring Revenue
Increasing consumables sales indicate progressing conversion from instrument placements to recurring usage. A higher share of consumables stabilizes revenues, improves predictability and margins over time, and leverages installed instruments to create durable pull-through economics as labs scale OGM workflows.
Negative Factors
Persistent Cash Burn
Sustained negative free cash flow means the company will likely rely on external financing absent material margin or revenue scale improvements. This creates dilution and execution risk, constrains investment in commercialization, and poses a multi‑quarter threat to strategic initiatives if cash runway shortens.
Read all positive and negative factors
Positive Factors
Negative Factors
Consumables Recurring Revenue
Increasing consumables sales indicate progressing conversion from instrument placements to recurring usage. A higher share of consumables stabilizes revenues, improves predictability and margins over time, and leverages installed instruments to create durable pull-through economics as labs scale OGM workflows.
Read all positive factors
BioNano Genomics Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue each business segment generates, highlighting which areas drive growth and which may need strategic adjustments.
Shows how much revenue each business segment generates, highlighting which areas drive growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyBioNano Genomics (BNGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.08M
Dividend YieldN/A
Average Volume (3M)170.51K
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue Growth0.96%
EPS Growth91.13%
CountryUS
Employees98
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-5.80
Shares Outstanding11,475,000
10 Day Avg. Volume142,259
30 Day Avg. Volume170,511
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.19
Price to Sales (P/S)0.29
P/FCF Ratio-0.51
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.53
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$5.00Price Target Upside208.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.6
Revenue Forecast (FY)$32.14M
BioNano Genomics Business Overview & Revenue Model
Company Description
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome usin...
How the Company Makes Money
BioNano Genomics primarily makes money by selling and supporting an instrument-led consumables model centered on its optical genome mapping platform. Key revenue streams include: (1) Instrument sales: upfront revenue from selling OGM instruments (...
BioNano Genomics Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call emphasized multiple positive operational and commercial developments: record Q1 flow cell unit sales, strong consumables growth, improved adjusted gross margin (49% vs 46% YoY), meaningful reimbursement wins that materially improve test economics, growing publication and clinical validation momentum, and balance sheet simplification through planned debt retirement. Offsetting these positives are continued revenue lumpiness (notably a 40% decline in software revenue due to a prior large sale), ongoing supply constraints that are improving, increased operating expenses ($9.1M vs $8.5M YoY) and a cash runway into 2027 with management not expecting cash flow breakeven in 2026. Overall, the call portrays improving commercialization traction and margin progress with material near-term financial and execution risks that management is addressing.Positive Updates
Revenue Growth and Guidance Reaffirmed
Q1 2026 revenue was $6.7 million, up 4% year-over-year and at the high end of guidance ($6.5M–$6.7M). Company reaffirmed full-year 2026 revenue guidance of $30M–$33M (growth of 5%–16% over 2025) and initiated Q2 2026 guidance of $7.5M–$7.8M (up 12%–16% vs Q2 2025).
Negative Updates
Large Decline in Software Revenue (Lumpy Sales)
Software revenue was $1.2 million in Q1 2026, down 40% year-over-year. Management explained this decline was driven by a very large software sale in the prior year that is expected to cover customer needs across 2025–2026, highlighting revenue lumpiness in software sales.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Guidance Reaffirmed
Q1 2026 revenue was $6.7 million, up 4% year-over-year and at the high end of guidance ($6.5M–$6.7M). Company reaffirmed full-year 2026 revenue guidance of $30M–$33M (growth of 5%–16% over 2025) and initiated Q2 2026 guidance of $7.5M–$7.8M (up 12%–16% vs Q2 2025).
Read all positive updates
Company Guidance
Bionano reaffirmed full‑year 2026 revenue guidance of $30.0–$33.0 million (up 5%–16% vs. 2025) and initiated Q2 guidance of $7.5–$7.8 million (up 12%–16% vs. Q2 2025); Q1 revenue was $6.7 million (at the high end of prior $6.5–$6.7M guidance). Key operational and profitability metrics supporting the outlook include 8,178 flow cells sold in Q1 (up 17% YoY and +21% to existing customers excluding new system sales), consumables revenue of $3.9M (up 20% YoY), software revenue of $1.2M (down 40% YoY), other revenue of $1.6M (up 36% YoY), adjusted gross margin of 49% (vs. 46% in Q1 2025) and adjusted operating expense of $9.1M (vs. $8.5M). The company ended Q1 with $24.7M in cash and equivalents (including $10.3M restricted), expects cash runway into 2027, plans to retire its senior secured convertible debt this month, does not expect cash‑flow breakeven in 2026 (aims to reduce burn toward Q4 2027), and cited strong reimbursement catalysts including a 47% increase in the hematologic malignancy CPT payment to $1,853.22 and a new constitutional OGM CPT payment determination of $1,263.53 effective Jan 1, 2026.BioNano Genomics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.74M | 28.51M | 30.78M | 36.12M | 27.80M | 17.98M |
| Gross Profit | 13.50M | 6.26M | 380.00K | 9.57M | 5.95M | 3.87M |
| EBITDA | -21.74M | -16.30M | -97.47M | -213.60M | -120.31M | -73.86M |
| Net Income | -31.60M | -26.39M | -112.02M | -232.49M | -132.60M | -72.44M |
Balance Sheet | ||||||
| Total Assets | 64.80M | 73.58M | 76.67M | 214.40M | 307.50M | 377.10M |
| Cash, Cash Equivalents and Short-Term Investments | 24.67M | 13.26M | 9.47M | 66.77M | 113.19M | 250.61M |
| Total Debt | 17.01M | 6.92M | 27.30M | 79.41M | 11.67M | 10.70M |
| Total Liabilities | 27.34M | 29.16M | 41.30M | 118.25M | 58.10M | 39.98M |
| Stockholders Equity | 37.46M | 44.42M | 35.38M | 96.16M | 249.40M | 337.12M |
Cash Flow | ||||||
| Free Cash Flow | -19.30M | -16.34M | -69.03M | -126.87M | -128.12M | -73.39M |
| Operating Cash Flow | -19.30M | -16.34M | -68.92M | -125.18M | -124.82M | -71.93M |
| Investing Cash Flow | 6.78M | -12.75M | 73.84M | 24.16M | 82.77M | -278.06M |
| Financing Cash Flow | 13.80M | 24.04M | -13.69M | 113.81M | 23.01M | 336.11M |
BioNano Genomics Technical Analysis
Negative
1.62
Price Trends
1.22
Negative
1.20
Negative
1.55
Negative
Market Momentum
-0.02
Positive
40.01
Neutral
3.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNGO, the sentiment is Negative. The current price of 1.62 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.22, and above the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 40.01 is Neutral, neither overbought nor oversold. The STOCH value of 3.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNGO.
BioNano Genomics Risk Analysis
BioNano Genomics disclosed 83 risk factors in its most recent earnings report. BioNano Genomics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNano Genomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $174.08M | -5.08 | -2101.40% | ― | 29.05% | 29.88% | |
54 Neutral | $511.21M | -7.53 | -6.70% | ― | 9.54% | -79.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $428.79M | -1.06 | -109.09% | ― | -0.28% | -286.80% | |
50 Neutral | $1.10B | -11.49 | -43.52% | ― | -24.71% | 21.16% | |
48 Neutral | $13.08M | -0.20 | -71.38% | ― | 0.96% | 91.13% | |
44 Neutral | $76.26M | -0.87 | -10.96% | ― | -0.21% | 75.40% |
* Healthcare Sector Average
BNGO
BioNano Genomics
1.14
-2.13
-65.14%
MYGN
Myriad Genetics
4.54
-0.32
-6.58%
FLGT
Fulgent Genetics
18.00
-1.33
-6.88%
PSNL
Personalis
10.54
4.33
69.73%
BNR
Burning Rock Biotech
7.25
3.88
115.13%
BDSX
Biodesix
16.81
11.44
213.04%
BioNano Genomics Corporate Events
Business Operations and StrategyExecutive/Board Changes
BioNano Genomics Announces Resignation of Chief Medical Officer
Negative
Jun 5, 2026
On June 2, 2026, Bionano Genomics, Inc. announced that its Chief Medical Officer, Alka Chaubey, Ph.D., had resigned, with her departure to take effect on July 5, 2026. The exit of the company’s top medical executive may prompt adjustments in...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
BioNano Genomics Retires Secured Debt, Boosts Flexibility
Positive
May 28, 2026
On May 28, 2026, Bionano Genomics, Inc. announced that it had fully retired and cancelled all of its outstanding Senior Secured Convertible Debentures, which had an aggregate face value of $20 million and were originally issued in May 2024. The co...
Executive/Board ChangesShareholder Meetings
BioNano Genomics Stockholders Approve 2026 Annual Meeting Proposals
Neutral
May 14, 2026
On May 14, 2026, Bionano Genomics, Inc. held its 2026 Annual Meeting of Stockholders, with 4,225,995 shares represented, or about 38.1% of shares outstanding and entitled to vote as of the March 19, 2026 record date. Shareholders elected Albert Lu...
Executive/Board Changes
BioNano Genomics Names Interim CEO Amid Leadership Transition
Negative
May 6, 2026
On May 5, 2026, Bionano Genomics terminated R. Erik Holmlin as president and chief executive officer, and he simultaneously resigned from the board, with severance to be provided under his employment agreement and an expected consulting role to su...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.